The global IVIG market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of the market is attributed to factors such as increasing prevalence of autoimmune disorders and rising awareness about the benefits of IVIG therapy.
Injection segment accounted for the largest share in 2018 and is expected to continue its dominance throughout the forecast period. The segment is projected to grow at a CAGR of 6% during 2019-2030, owing to its high demand in developed countries such as North America and Europe.
North America accounted for the largest share in 2018 and is expected to continue its dominance throughout the forecast period due to high adoption rates among patients with autoimmune disorders such as MS, MG, MMN, MADSAM, dermatomyositis (DM), polymyositis (PM).
- IVIG is a relatively new treatment for autoimmune diseases, so there is still a lot of room for growth in the market.
- The market for IVIG is growing as more people are diagnosed with autoimmune diseases and need treatment.
- The market for IVIG will grow as more people are diagnosed with autoimmune diseases and need treatment, but it will also shrink if the number of people being diagnosed decreases or if treatments become less expensive or more effective.
- There are many different types of IVIG available on the market, which means that there is room to grow in this area as well because not all patients respond to one type of IVIG and may need to try another type before finding one that works best for them.
- As new treatments come out, they can be used alongside other treatments like steroids or immunosuppressants to help treat autoimmune disease symptoms.
Industry Growth Insights published a new data on “IVIG Market”. The research report is titled “IVIG Market research by Types (Injection, Lyophilized Powder), By Applications (Multiple Sclerosis (MS), Myasthenia Gravis (MG), Multifocal Motor Neuropathy (MMN), Multifocal Acquired Sensory and Motor Neuropathy (MADSAM), Dermatomyositis, Polymyositis), By Players/Companies Green Cross, BSV, Hualan Bio, RAAS, YUAN DA SHUYANG, Kangbao Bio, Tiantan Bio, Taibang Bio, Weiguang Bio, SIBP, TONROL, RUIDE Bio, BOYA Bio, RUIDE Bio, Xinxing Medicine, Weilun Bio, WIBP”.
Scope Of The Report
Report Attributes
Report Details
Report Title
IVIG Market Research Report
By Type
Injection, Lyophilized Powder
By Application
Multiple Sclerosis (MS), Myasthenia Gravis (MG), Multifocal Motor Neuropathy (MMN), Multifocal Acquired Sensory and Motor Neuropathy (MADSAM), Dermatomyositis, Polymyositis
By Companies
Green Cross, BSV, Hualan Bio, RAAS, YUAN DA SHUYANG, Kangbao Bio, Tiantan Bio, Taibang Bio, Weiguang Bio, SIBP, TONROL, RUIDE Bio, BOYA Bio, RUIDE Bio, Xinxing Medicine, Weilun Bio, WIBP
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global IVIG Market Report Segments:
The global IVIG market is segmented on the basis of:
Types
Injection, Lyophilized Powder
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Multiple Sclerosis (MS), Myasthenia Gravis (MG), Multifocal Motor Neuropathy (MMN), Multifocal Acquired Sensory and Motor Neuropathy (MADSAM), Dermatomyositis, Polymyositis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Green Cross
- BSV
- Hualan Bio
- RAAS
- YUAN DA SHUYANG
- Kangbao Bio
- Tiantan Bio
- Taibang Bio
- Weiguang Bio
- SIBP
- TONROL
- RUIDE Bio
- BOYA Bio
- RUIDE Bio
- Xinxing Medicine
- Weilun Bio
- WIBP
Highlights of The IVIG Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Lyophilized Powder
- By Application:
- Multiple Sclerosis (MS)
- Myasthenia Gravis (MG)
- Multifocal Motor Neuropathy (MMN)
- Multifocal Acquired Sensory and Motor Neuropathy (MADSAM)
- Dermatomyositis
- Polymyositis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the IVIG Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
IVIG is a type of intravenous immunoglobulin. IVIG helps the body fight infections by providing antibodies to help the body mount an immune response.
Some of the key players operating in the ivig market are Green Cross, BSV, Hualan Bio, RAAS, YUAN DA SHUYANG, Kangbao Bio, Tiantan Bio, Taibang Bio, Weiguang Bio, SIBP, TONROL, RUIDE Bio, BOYA Bio, RUIDE Bio, Xinxing Medicine, Weilun Bio, WIBP.
The ivig market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. IVIG Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. IVIG Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. IVIG Market - Supply Chain
4.5. Global IVIG Market Forecast
4.5.1. IVIG Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. IVIG Market Size (000 Units) and Y-o-Y Growth
4.5.3. IVIG Market Absolute $ Opportunity
5. Global IVIG Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. IVIG Market Size and Volume Forecast by Type
5.3.1. Injection
5.3.2. Lyophilized Powder
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global IVIG Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. IVIG Market Size and Volume Forecast by Application
6.3.1. Multiple Sclerosis (MS)
6.3.2. Myasthenia Gravis (MG)
6.3.3. Multifocal Motor Neuropathy (MMN)
6.3.4. Multifocal Acquired Sensory and Motor Neuropathy (MADSAM)
6.3.5. Dermatomyositis
6.3.6. Polymyositis
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global IVIG Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. IVIG Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global IVIG Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. IVIG Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global IVIG Demand Share Forecast, 2019-2026
9. North America IVIG Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America IVIG Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America IVIG Market Size and Volume Forecast by Application
9.4.1. Multiple Sclerosis (MS)
9.4.2. Myasthenia Gravis (MG)
9.4.3. Multifocal Motor Neuropathy (MMN)
9.4.4. Multifocal Acquired Sensory and Motor Neuropathy (MADSAM)
9.4.5. Dermatomyositis
9.4.6. Polymyositis
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America IVIG Market Size and Volume Forecast by Type
9.7.1. Injection
9.7.2. Lyophilized Powder
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America IVIG Demand Share Forecast, 2019-2026
10. Latin America IVIG Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America IVIG Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America IVIG Market Size and Volume Forecast by Application
10.4.1. Multiple Sclerosis (MS)
10.4.2. Myasthenia Gravis (MG)
10.4.3. Multifocal Motor Neuropathy (MMN)
10.4.4. Multifocal Acquired Sensory and Motor Neuropathy (MADSAM)
10.4.5. Dermatomyositis
10.4.6. Polymyositis
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America IVIG Market Size and Volume Forecast by Type
10.7.1. Injection
10.7.2. Lyophilized Powder
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America IVIG Demand Share Forecast, 2019-2026
11. Europe IVIG Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe IVIG Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe IVIG Market Size and Volume Forecast by Application
11.4.1. Multiple Sclerosis (MS)
11.4.2. Myasthenia Gravis (MG)
11.4.3. Multifocal Motor Neuropathy (MMN)
11.4.4. Multifocal Acquired Sensory and Motor Neuropathy (MADSAM)
11.4.5. Dermatomyositis
11.4.6. Polymyositis
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe IVIG Market Size and Volume Forecast by Type
11.7.1. Injection
11.7.2. Lyophilized Powder
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe IVIG Demand Share, 2019-2026
12. Asia Pacific IVIG Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific IVIG Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific IVIG Market Size and Volume Forecast by Application
12.4.1. Multiple Sclerosis (MS)
12.4.2. Myasthenia Gravis (MG)
12.4.3. Multifocal Motor Neuropathy (MMN)
12.4.4. Multifocal Acquired Sensory and Motor Neuropathy (MADSAM)
12.4.5. Dermatomyositis
12.4.6. Polymyositis
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific IVIG Market Size and Volume Forecast by Type
12.7.1. Injection
12.7.2. Lyophilized Powder
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific IVIG Demand Share, 2019-2026
13. Middle East & Africa IVIG Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa IVIG Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa IVIG Market Size and Volume Forecast by Application
13.4.1. Multiple Sclerosis (MS)
13.4.2. Myasthenia Gravis (MG)
13.4.3. Multifocal Motor Neuropathy (MMN)
13.4.4. Multifocal Acquired Sensory and Motor Neuropathy (MADSAM)
13.4.5. Dermatomyositis
13.4.6. Polymyositis
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa IVIG Market Size and Volume Forecast by Type
13.7.1. Injection
13.7.2. Lyophilized Powder
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa IVIG Demand Share, 2019-2026
14. Competition Landscape
14.1. Global IVIG Market: Market Share Analysis
14.2. IVIG Distributors and Customers
14.3. IVIG Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Green Cross
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. BSV
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Hualan Bio
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. RAAS
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. YUAN DA SHUYANG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Kangbao Bio
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Tiantan Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Taibang Bio
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Weiguang Bio
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. SIBP
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. TONROL
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. RUIDE Bio
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. BOYA Bio
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. RUIDE Bio
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Xinxing Medicine
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Weilun Bio
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. WIBP
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
